Phase II study of intravenous adenosine 5′-triphosphate in patients with previously untreated stage IIIB and stage IV non-small cell lung cancer
Phase II study of intravenous adenosine 5′-triphosphate in patients with previously untreated stage IIIB and stage IV non-small cell lung cancer
复制标题
DOI：
10.1023/a:1006018610986
复制
发表时间：
1998-01-01
影响因子：
3.4
通讯作者：
Figlin, RA
中科院分区：
文献类型：
--
作者：
Haskell, CM;Mendoza, E;Figlin, RA
15例IIIB或IV期非小细胞肺癌患者提供了知情同意书，接受三次或更多次96小时输注ATP，剂量为50 mcg/kg/min或更高，以确定ATP是否对该肿瘤类型具有抗肿瘤活性，并更好地定义ATP作为单药给药的毒性谱。未观察到客观的完全或部分缓解。总体组的中位生存期为187天，肿瘤进展的中位时间为113天。主要毒副作用为胸痛和呼吸困难，5例患者因药物不良反应而停止治疗。我们的结论是，ATP在这个剂量和时间表的管理是一个无效的代理人在晚期非小细胞肺癌患者。
Fifteen patients with Stage IIIB or IV non-small cell lung cancer gave informed consent to receive three or more 96-hour infusions of ATP at a dose of 50 mcg/kg/min or higher to determine whether ATP has antineoplastic activity against this tumor type and to better define the spectrum of toxicity for ATP given as a single agent. There were no objective complete or partial responses observed. The median survival of the overall group was 187 days and the median time to tumor progression was 113 days. The major toxic side effects were chest pain and dyspnea, leading to the cessation of treatment in 5 patients. We conclude that ATP at this dose and schedule of administration is an inactive agent in patients with advanced non-small cell lung cancer.